Table 3 Time-varying HR estimates^a from a fixed-effects NMA of RFS/DFS (p1 = 0, p2 = −1, scale, shape ×1) in patients with resected stage II–IV melanoma

NIVO vs. OBS/PBO

0.58 (0.43–0.77)

0.51 (0.33–0.80)

0.46 (0.26–0.86)

0.43 (0.21–0.91)

NIVO vs. DAB+TRAM

1.02 (0.71–1.47)

0.46 (0.27–0.78)

0.28 (0.14–0.59)

0.20 (0.08–0.49)

NIVO vs. PEM

1.19 (0.81–1.76)

1.06 (0.56–2.05)

0.96 (0.40–2.29)

0.88 (0.30–2.51)

NIVO vs. IPI (10 mg/kg)

0.69 (0.55–0.86)

0.66 (0.46–0.96)

0.65 (0.40–1.07)

0.64 (0.35–1.17)

NIVO vs. IPI (3 mg/kg)

0.75 (0.54–1.04)

0.93 (0.58–1.48)

1.06 (0.57–2.01)

1.16 (0.54–2.55)

NIVO vs. CHEM

0.63 (0.44–0.89)

0.53 (0.32–0.86)

0.47 (0.24–0.91)

0.42 (0.19–0.95)

NIVO vs. IFN

0.64 (0.48–0.86)

0.55 (0.36–0.88)

0.49 (0.27–0.93)

0.46 (0.22–0.97)